Robbins Arroyo LLP: Array BioPharma Inc. (ARRY) Misled Shareholders According to a Recently Filed Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Array BioPharma Inc. (NasdaqGM: ARRY). The complaint
is brought on behalf of all purchasers of Array securities between December 16, 2015 and March 17, 2017, for alleged violations of
the Securities Exchange Act of 1934 by Array's officers and directors. Array, a biopharmaceutical company, develops small molecule
drugs to treat patients with cancer in North America, Europe, and the Asian Pacific. Array's lead cancer drug is known as
binimetinib and is designed to treat NRAS-mutant melanoma.
View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/array-biopharma-inc
Array Accused of Touting False Promises About Its Drug
According to the complaint, on December 16, 2015, Array announced positive results from the company's Phase 3 NEMO trial, "which
suggest binimetinib has the potential to provide an important new treatment option for patients with advanced NRAS melanoma." The
company continued to tout binimetinib, calling it the "first and only MEK inhibitor to demonstrate improvement on progression free
survival in a Phase 3 trial for NRAS mutant melanoma patients." Array, however, was aware that NEMO's lack of supporting clinical
data would be insufficient for binimetinib to receive approval by the U.S. Food and Drug Administration. On March 19, 2017, Array
announced the withdrawal of the binimetinib new drug application, subsequently calling it a clear setback for the company and
management's regulatory and commercial strategy. As the truth was revealed over the course of two trading days, Array's stock fell
over 14% to close at $9.13 per share on March 21, 2017.
Array Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid
Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the
shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional
investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion
of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
Robbins Arroyo LLP
Leonid Kandinov
(619) 525-3990 or Toll Free (800) 350-6003
LKandinov@robbinsarroyo.com
www.robbinsarroyo.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20171127006089/en/